ConductScience.org, home

Comparison · NCT01516216-deaths

Chemotherapy + Standard Dose Vitamin D vs Chemotherapy + Higher Dose Vitamin D: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Chemotherapy + Standard Dose Vitamin D vs Chemotherapy + Higher Dose Vitamin D: deaths from any cause. Trial comparisons, record NCT01516216-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01516216-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.8060.6960.883wilson
Risk in group 20.6620.5430.763wilson
Risk difference, group 1 minus group 20.144-0.005310.285newcombe hybrid score
Risk ratio, group 1 over group 21.220.9911.5log
Odds ratio, group 1 over group 22.120.9674.66log
Number needed to harm, for one more death from any cause on Chemotherapy + Standard Dose Vitamin D than on Chemotherapy + Higher Dose Vitamin D6.93from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Chemotherapy + Standard Dose Vitamin D
FOLFOX-bevacizumab: intravenously on Day 1 (+/- 7 days) of every two-week cycle per institutional standards + 400 IU vitamin D3 orally once daily~Participants were treated until disease progression, unacceptable toxicity or withdrawal for other reasons.
5467EG000
Group 2Chemotherapy + Higher Dose Vitamin D
FOLFOX-bevacizumab: intravenously on Day 1 (+/- 7 days) of every two-week cycle per institutional standards + 8000 IU daily x 2 weeks as loading dose, followed by 4000 IU daily as maintenance dose.~Participants were treated until disease progression, unacceptable toxicity or withdrawal for other reasons.
4568EG001

Harm

What it counts
Total, all-cause mortality
Time frame
AEs were evaluated at day 1 of each cycle on treatment and up to 30 days after the last dose. Maximum treatment duration is 28.5 months with median 7.3 months. All-Cause Mortality was assessed up to 56.7 months and Serious and Other (Not Including Serious) adverse events were assessed up to 29.5 months (the additional 30 days of monitoring included in the maximum treatment duration).

Source ClinicalTrials.gov

Trial

Title
Study of Vitamin D in Untreated Metastatic Colorectal Cancer
NCT number
NCT01516216
Phases
PHASE2
Conditions
Metastatic Colorectal Cancer
Interventions
FOLFOX + bevacizumab, Vitamin D
Lead sponsor
Dana-Farber Cancer Institute
Results first posted
2022-03-23

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01516216-deaths